Amneal Pharmaceuticals Stock

Amneal Pharmaceuticals Equity 2024

Amneal Pharmaceuticals Equity

19.78 M USD

Ticker

AMRX

ISIN

US03168L1052

WKN

A2JLMD

In 2024, Amneal Pharmaceuticals's equity was 19.78 M USD, a -93.37% increase from the 298.42 M USD equity in the previous year.

Amneal Pharmaceuticals Aktienanalyse

What does Amneal Pharmaceuticals do?

Amneal Pharmaceuticals Inc is a leading pharmaceutical company headquartered in Bridgewater, New Jersey, USA. It was founded in 2002 by Chirag Patel and Chintu Patel, both of whom were involved in the generic pharmaceutical industry. Amneal specializes in the development, manufacturing, and marketing of high-quality, cost-effective generic and specialty pharmaceuticals for a variety of therapeutic areas. The company's mission is to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal operates globally in over 50 countries, with global facilities in India, Ireland, and other countries. The company strives to provide innovation, exceptional service, and reliability to customers and patients worldwide. Over the years, the company has rapidly grown to become a major player in the global pharmaceutical market. It offers a wide range of products, including both generic and specialty pharmaceuticals in numerous therapy areas. These areas include oncology, central nervous system (CNS), gastroenterology, dermatology, immunology, pain management, and many others. Amneal places a strong emphasis on clinical research and development to create innovative medications and therapies that meet the needs of today's patients. The company has multiple research and development centers worldwide, including in Israel, India, and the USA, where it collaborates closely with industry partners to develop new products. Another hallmark of Amneal is its ability to provide high-quality generic pharmaceuticals that meet the needs of customers in different countries and regions. The company manufactures its products to the highest standards and has a strict quality assurance system to ensure that patients can rely on receiving medications of the highest quality and efficacy. Amneal's product line is extensive, encompassing a variety of drugs ranging from simple over-the-counter (OTC) preparations to complex steroids and oncology therapeutics. Some of its key products include Tamoxifen Citrate, Lamotrigine, Methylphenidate Hydrochloride, Warfarin Sodium, Buprenorphine-Naloxone, and many others. Amneal Pharmaceuticals also forms partnerships with other companies to expand and diversify its business model. In 2018, Amneal merged with Impax Laboratories, Inc., a leading pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty products for various therapy areas. The merger brought together both companies, creating an entity with a broader product portfolio, a larger global reach, and stronger development and marketing expertise. In summary, Amneal Pharmaceuticals Inc is a leading pharmaceutical company focused on the development and marketing of generic and specialty pharmaceuticals for a variety of therapeutic areas. The company is on a mission to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal prioritizes clinical research and development to create innovative medications and therapies, and it has a strict quality assurance system. The company has a wide product range and collaborates closely with other companies to expand its business model and global reach. Amneal Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Amneal Pharmaceuticals's Equity

Amneal Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Amneal Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Amneal Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Amneal Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Amneal Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Amneal Pharmaceuticals stock

What is the equity of Amneal Pharmaceuticals this year?

Amneal Pharmaceuticals has equity of 19.78 M USD this year.

What was the equity of Amneal Pharmaceuticals compared to the previous year?

The equity of Amneal Pharmaceuticals has increased/decreased by -93.37% decreased compared to the previous year.

What impact does a high equity have on investors of Amneal Pharmaceuticals?

A high equity is advantageous for investors of Amneal Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Amneal Pharmaceuticals?

A low equity can be a risk for investors of Amneal Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Amneal Pharmaceuticals affect the company?

An increase in equity of Amneal Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Amneal Pharmaceuticals affect the company?

A reduction in equity of Amneal Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Amneal Pharmaceuticals?

Some factors that can affect the equity of Amneal Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Amneal Pharmaceuticals so important for investors?

The equity of Amneal Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Amneal Pharmaceuticals take to change the equity?

To change equity, Amneal Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Amneal Pharmaceuticals pay?

Over the past 12 months, Amneal Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amneal Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Amneal Pharmaceuticals?

The current dividend yield of Amneal Pharmaceuticals is .

When does Amneal Pharmaceuticals pay dividends?

Amneal Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amneal Pharmaceuticals?

Amneal Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Amneal Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amneal Pharmaceuticals located?

Amneal Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amneal Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amneal Pharmaceuticals from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did Amneal Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of Amneal Pharmaceuticals in the year 2023?

In the year 2023, Amneal Pharmaceuticals distributed 0 USD as dividends.

In which currency does Amneal Pharmaceuticals pay out the dividend?

The dividends of Amneal Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Amneal Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Amneal Pharmaceuticals

Our stock analysis for Amneal Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amneal Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.